{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:13:49Z","timestamp":1788542029703,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK132408"],"award-info":[{"award-number":["DK132408"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40262-026-01682-w","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:41:45Z","timestamp":1785134505000},"page":"1377-1388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"65","author":[{"given":"Sanjana","family":"Parikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Irie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Nadai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Minar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8471-9826","authenticated-orcid":false,"given":"Tomoyuki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"1682_CR1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41120","author":"MA Muzammil","year":"2023","unstructured":"Muzammil MA, Fariha F, Patel T, et al. Advancements in inflammatory bowel disease: a narrative review of diagnostics, management, epidemiology, prevalence, patient outcomes, quality of life, and clinical presentation. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.41120.","journal-title":"Cureus"},{"issue":"suppl_1","key":"1682_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.MIB.0000195385.19268.68","volume":"12","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12(suppl_1):S3\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"1682_CR3","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/17474124.2019.1685872","volume":"13","author":"JJ Ashton","year":"2019","unstructured":"Ashton JJ, Green Z, Kolimarala V, Beattie RM. Inflammatory bowel disease: long-term therapeutic challenges. Expert Rev Gastroenterol Hepatol. 2019;13(11):1049\u201363. https:\/\/doi.org\/10.1080\/17474124.2019.1685872.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"1682_CR4","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1053\/j.gastro.2021.09.076","volume":"162","author":"C Le Berre","year":"2022","unstructured":"Le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving short- and long-term goals of management of inflammatory bowel diseases: getting it right, making it last. Gastroenterology. 2022;162(5):1424\u201338. https:\/\/doi.org\/10.1053\/j.gastro.2021.09.076.","journal-title":"Gastroenterology"},{"key":"1682_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/2040622319899297","author":"K Hazel","year":"2020","unstructured":"Hazel K, O\u2019Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis. 2020. https:\/\/doi.org\/10.1177\/2040622319899297.","journal-title":"Ther Adv Chronic Dis"},{"key":"1682_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.612830","author":"M Luzentales-Simpson","year":"2021","unstructured":"Luzentales-Simpson M, Pang YCF, Zhang A, Sousa JA, Sly LM. Vedolizumab: potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases. Front Cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/fcell.2021.612830.","journal-title":"Front Cell Dev Biol."},{"issue":"12","key":"1682_CR7","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","volume":"10","author":"T Wyant","year":"2016","unstructured":"Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10(12):1437\u201344. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw092.","journal-title":"J Crohns Colitis"},{"issue":"9","key":"1682_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2217\/imt.12.85","volume":"4","author":"LP McLean","year":"2012","unstructured":"McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohns disease. Immunotherapy. 2012;4(9):883\u201398. https:\/\/doi.org\/10.2217\/imt.12.85.","journal-title":"Immunotherapy"},{"issue":"5","key":"1682_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut. 2017;66(5):839\u201351. https:\/\/doi.org\/10.1136\/gutjnl-2015-311079.","journal-title":"Gut"},{"issue":"9","key":"1682_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/14740338.2023.2247976","volume":"22","author":"S Honap","year":"2023","unstructured":"Honap S, Netter P, Danese S, Peyrin-Biroulet L. An update on the safety of long-term vedolizumab use in inflammatory bowel disease. Expert Opin Drug Saf. 2023;22(9):767\u201376. https:\/\/doi.org\/10.1080\/14740338.2023.2247976.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"1682_CR11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1124\/jpet.109.153973","volume":"330","author":"D Soler","year":"2009","unstructured":"Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-\u03b14\u03b27 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864\u201375. https:\/\/doi.org\/10.1124\/jpet.109.153973.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1682_CR12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/1756283X16635081","volume":"9","author":"N Shahidi","year":"2016","unstructured":"Shahidi N, Bressler B, Panaccione R. The role of vedolizumab in patients with moderate-to-severe Crohn\u2019s disease and ulcerative colitis. Therap Adv Gastroenterol. 2016;9(3):330\u20138. https:\/\/doi.org\/10.1177\/1756283X16635081.","journal-title":"Therap Adv Gastroenterol."},{"issue":"40","key":"1682_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030590","volume":"101","author":"B Qiu","year":"2022","unstructured":"Qiu B, Liang JX, Li C. Efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2022;101(40):e30590. https:\/\/doi.org\/10.1097\/MD.0000000000030590.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"1682_CR14","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.dld.2018.07.007","volume":"50","author":"MV Lenti","year":"2018","unstructured":"Lenti MV, Levison S, Eliadou E, et al. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: the Cross Pennine study. Dig Liver Dis. 2018;50(12):1299\u2013304. https:\/\/doi.org\/10.1016\/j.dld.2018.07.007.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"1682_CR15","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","volume":"147","author":"OJ Adedokun","year":"2014","unstructured":"Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147(6):1296-1307.e5. https:\/\/doi.org\/10.1053\/j.gastro.2014.08.035.","journal-title":"Gastroenterology"},{"issue":"10","key":"1682_CR16","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","volume":"4","author":"EA Maser","year":"2006","unstructured":"Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2006;4(10):1248\u201354. https:\/\/doi.org\/10.1016\/j.cgh.2006.06.025.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"1682_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/ibd.21831","volume":"18","author":"JF Colombel","year":"2012","unstructured":"Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(2):349\u201358. https:\/\/doi.org\/10.1002\/ibd.21831.","journal-title":"Inflamm Bowel Dis"},{"issue":"21","key":"1682_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10214990","volume":"10","author":"BP Vaughn","year":"2021","unstructured":"Vaughn BP. A practical guide to therapeutic drug monitoring of biologic medications for inflammatory bowel disease. J Clin Med. 2021;10(21):4990. https:\/\/doi.org\/10.3390\/jcm10214990.","journal-title":"J Clin Med"},{"issue":"4","key":"1682_CR19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/apt.15113","volume":"49","author":"MT Osterman","year":"2019","unstructured":"Osterman MT, Rosario M, Lasch K, et al. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. Aliment Pharmacol Ther. 2019;49(4):408\u201318. https:\/\/doi.org\/10.1111\/apt.15113.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"1682_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103142","volume":"9","author":"BP Vaughn","year":"2020","unstructured":"Vaughn BP, Yarur AJ, Graziano E, et al. Vedolizumab serum trough concentrations and response to dose escalation in inflammatory bowel disease. J Clin Med. 2020;9(10):3142. https:\/\/doi.org\/10.3390\/jcm9103142.","journal-title":"J Clin Med"},{"issue":"10","key":"1682_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer L, Niederalt C, Wendl T, et al. Applied concepts in PBPK modeling: how to build a PBPK\/PD model. CPT Pharmacometr Syst Pharmacol. 2016;5(10):516\u201331. https:\/\/doi.org\/10.1002\/psp4.12134.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"9","key":"1682_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12091974","volume":"12","author":"Z Petric","year":"2024","unstructured":"Petric Z, Gon\u00e7alves J, Paix\u00e3o P. Infliximab in inflammatory bowel disease: leveraging physiologically based pharmacokinetic modeling in the clinical context. Biomedicines. 2024;12(9):1974. https:\/\/doi.org\/10.3390\/biomedicines12091974.","journal-title":"Biomedicines"},{"issue":"1","key":"1682_CR23","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/bcp.14963","volume":"88","author":"HP Chang","year":"2022","unstructured":"Chang HP, Shakhnovich V, Frymoyer A, et al. A population physiologically\u2010based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab. Br J Clin Pharmacol. 2022;88(1):290\u2013302. https:\/\/doi.org\/10.1111\/bcp.14963.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1682_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1208\/s12248-012-9446-2","volume":"15","author":"HM Jones","year":"2013","unstructured":"Jones HM, Mayawala K, Poulin P. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. AAPS J. 2013;15(2):377\u201387. https:\/\/doi.org\/10.1208\/s12248-012-9446-2.","journal-title":"AAPS J"},{"key":"1682_CR25","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9640-5","author":"L Li","year":"2014","unstructured":"Li L, Gardner I, Dostalek M, Jamei M. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model. AAPS J. 2014. https:\/\/doi.org\/10.1208\/s12248-014-9640-5.","journal-title":"AAPS J"},{"issue":"10","key":"1682_CR26","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s11095-005-6650-0","volume":"22","author":"DE Mager","year":"2005","unstructured":"Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005;22(10):1589\u201396. https:\/\/doi.org\/10.1007\/s11095-005-6650-0.","journal-title":"Pharm Res"},{"issue":"5","key":"1682_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10928-008-9102-8","volume":"35","author":"L Gibiansky","year":"2008","unstructured":"Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008;35(5):573\u201391. https:\/\/doi.org\/10.1007\/s10928-008-9102-8.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1682_CR28","unstructured":"U.S. Food and Drug Administration. Clinical Pharmacology and Biopharmaceutics Review(s) 1 addendum to Office of Clinical Pharmacology Review. In: Application Number: 125476orig1s000. Center for Drug Evaluation and Research. 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125476Orig1s000ClinPharmR.pdf. Accessed 19 Dec 2025."},{"issue":"11","key":"1682_CR29","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s40261-016-0437-4","volume":"36","author":"M Rosario","year":"2016","unstructured":"Rosario M, Wyant T, Leach T, et al. Vedolizumab pharmacokinetics, pharmacodynamics, safety, and tolerability following administration of a single, ascending, intravenous dose to healthy volunteers. Clin Drug Investig. 2016;36(11):913\u201323. https:\/\/doi.org\/10.1007\/s40261-016-0437-4.","journal-title":"Clin Drug Investig"},{"issue":"11","key":"1682_CR30","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s40262-017-0546-0","volume":"56","author":"M Rosario","year":"2017","unstructured":"Rosario M, Dirks NL, Milch C, et al. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. Clin Pharmacokinet. 2017;56(11):1287\u2013301. https:\/\/doi.org\/10.1007\/s40262-017-0546-0.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1682_CR31","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ibd.21896","volume":"18","author":"A Parikh","year":"2012","unstructured":"Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18(8):1470\u20139. https:\/\/doi.org\/10.1002\/ibd.21896.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"1682_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/nejmoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710. https:\/\/doi.org\/10.1056\/nejmoa1215734.","journal-title":"N Engl J Med"},{"issue":"8","key":"1682_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1215739.","journal-title":"N Engl J Med"},{"issue":"2","key":"1682_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/jcph.1307","volume":"59","author":"K Kobayashi","year":"2019","unstructured":"Kobayashi K, Suzuki Y, Watanabe K, et al. A phase 1, multiple-dose study of vedolizumab in Japanese patients with ulcerative colitis. J Clin Pharmacol. 2019;59(2):271\u20139. https:\/\/doi.org\/10.1002\/jcph.1307.","journal-title":"J Clin Pharmacol"},{"key":"1682_CR35","unstructured":"Phase III study of MLN0002 (300 mg) in the treatment of Japanese patients with moderately or severely active ulcerative colitis. ClinicalTrials.gov\u00a0identifier: NCT02039505. Updated: April 25, 2019. https:\/\/clinicaltrials.gov\/study\/NCT02039505. Accessed 19 Dec 2025.34."},{"key":"1682_CR36","unstructured":"Phase III Study of MLN0002 (300 mg) in the treatment of Japanese participants with moderately or severely active\u00a0Crohn's\u00a0disease. ClinicalTrials.gov identifier: NCT02038920. Updated: December 9, 2019. https:\/\/clinicaltrials.gov\/study\/NCT02038920. Accessed 19 Dec 2025.35."},{"issue":"4","key":"1682_CR37","doi-asserted-by":"publisher","first-page":"e0215491","DOI":"10.1371\/journal.pone.021549136","volume":"14","author":"S Motoya","year":"2019","unstructured":"Motoya S, Watanabe K, Ogata H, et al. Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study. PLoS ONE. 2019;14(4):e0215491. https:\/\/doi.org\/10.1371\/journal.pone.021549136.","journal-title":"PLoS ONE"},{"issue":"5","key":"1682_CR38","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1080\/19420862.2019.1605270","volume":"11","author":"S Chung","year":"2019","unstructured":"Chung S, Nguyen V, Lin YL, et al. An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans. MAbs. 2019;11(5):942\u201355. https:\/\/doi.org\/10.1080\/19420862.2019.1605270.","journal-title":"MAbs"},{"issue":"1","key":"1682_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/prp2.98","volume":"3","author":"H Li","year":"2015","unstructured":"Li H, K\u00f6ck K, Wisler JA, et al. Prediction of clinical pharmacokinetics of AMG 181, a human anti-\u03b14\u03b27 monoclonal antibody for treating inflammatory bowel diseases. Pharmacol Res Perspect. 2015;3(1):1\u201313. https:\/\/doi.org\/10.1002\/prp2.98.","journal-title":"Pharmacol Res Perspect"},{"key":"1682_CR40","volume-title":"Guyton and Hall textbook of medical physiology","author":"AC Guyton","year":"2011","unstructured":"Guyton AC, Hall JE. Guyton and Hall textbook of medical physiology. Elsevier; 2011."},{"issue":"2","key":"1682_CR41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/gut.40.2.241","volume":"40","author":"J Meenan","year":"1997","unstructured":"Meenan J, Spaans J, Grool TA, Pals ST, Tytgat GN, van Deventer SJ. Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation. Gut. 1997;40(2):241\u20136. https:\/\/doi.org\/10.1136\/gut.40.2.241.","journal-title":"Gut"},{"key":"1682_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.clim.2018.05.006","volume":"193","author":"JD Lord","year":"2018","unstructured":"Lord JD, Long SA, Shows DM, et al. Circulating integrin alpha4\/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype. Clin Immunol. 2018;193:24\u201332. https:\/\/doi.org\/10.1016\/j.clim.2018.05.006.","journal-title":"Clin Immunol"},{"key":"1682_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01700","author":"T Rath","year":"2018","unstructured":"Rath T, Billmeier U, Ferrazzi F, et al. Effects of anti-integrin treatment with vedolizumab on immune pathways and cytokines in inflammatory bowel diseases. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.01700.","journal-title":"Front Immunol"},{"issue":"8","key":"1682_CR44","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/apt.15484","volume":"50","author":"S Singh","year":"2019","unstructured":"Singh S, Dulai PS, Vande Casteele N, et al. Systematic review with meta\u2010analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2019;50(8):848\u201357. https:\/\/doi.org\/10.1111\/apt.15484.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"1682_CR45","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.cgh.2018.04.040","volume":"16","author":"E Dreesen","year":"2018","unstructured":"Dreesen E, Verstockt B, Bian S, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(12):1937-1946.e8. https:\/\/doi.org\/10.1016\/j.cgh.2018.04.040.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"1682_CR46","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10928-017-9515-3","volume":"44","author":"PRV Malik","year":"2017","unstructured":"Malik PRV, Hamadeh A, Phipps C, Edginton AN. Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability. J Pharmacokinet Pharmacodyn. 2017;44(3):277\u201390. https:\/\/doi.org\/10.1007\/s10928-017-9515-3.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1682_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.974423","author":"W Huang","year":"2022","unstructured":"Huang W, Stader F, Chan P, et al. Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.974423.","journal-title":"Front Pharmacol"},{"key":"1682_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106807","volume":"199","author":"X Cai","year":"2024","unstructured":"Cai X, Wu W, Guo G, et al. Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of ustekinumab in pediatric patients with inflammatory bowel disease. Eur J Pharm Sci. 2024;199:106807. https:\/\/doi.org\/10.1016\/j.ejps.2024.106807.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"1682_CR49","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/apt.13243","volume":"42","author":"M Rosario","year":"2015","unstructured":"Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn\u2019s disease. Aliment Pharmacol Ther. 2015;42(2):188\u2013202. https:\/\/doi.org\/10.1111\/apt.13243.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"1682_CR50","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/apt.17277","volume":"57","author":"RJ Colman","year":"2023","unstructured":"Colman RJ, Mizuno T, Fukushima K, et al. Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance. Aliment Pharmacol Ther. 2023;57(5):524\u201339. https:\/\/doi.org\/10.1111\/apt.17277.","journal-title":"Aliment Pharmacol Ther"},{"key":"1682_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14060541","author":"R Tanaka","year":"2025","unstructured":"Tanaka R, Irie K, Mizuno T. Physiologically based pharmacokinetic modeling of antibiotics in children: perspectives on model-informed precision dosing. Antibiotics. 2025. https:\/\/doi.org\/10.3390\/antibiotics14060541.","journal-title":"Antibiotics"},{"issue":"8","key":"1682_CR52","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1080\/00365521.2021.1938206","volume":"56","author":"S Kolehmainen","year":"2021","unstructured":"Kolehmainen S, Ylisaukko-oja T, et al. Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting. Scand J Gastroenterol. 2021;56(8):906\u201313. https:\/\/doi.org\/10.1080\/00365521.2021.1938206.","journal-title":"Scand J Gastroenterol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01682-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01682-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01682-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:23:14Z","timestamp":1788538994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01682-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1682"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01682-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All datasets used in this study are appropriately cited in the manuscript (see references).","order":2,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The model simulation files are accessible upon reasonable request by contacting the corresponding author.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SP, KI, and TM wrote the manuscript, and all authors contributed to the revision of the draft manuscript. SP, KI, PM, RT, and TM designed the research, and SP, KI, TN, RT, and TM analyzed the data.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}